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Abstract
We describe here the ﬁrst case of osteitis caused by Candida hae-
mulonii in a young immunocompetent patient. This patient
presented a history of severe peripheral vascular disease associ-
ated with a lack of hygienic conditions as the only risk factors for
such an uncommon infection. Clinical signs and histological exami-
nation allowed us to determine that it was a C. haemulonii infection
and not colonization. The outcome was favourable with oral
voriconazole therapy and surgical revascularization. An environ-
mental cause of such infections is most probable, as C. haemulonii
has previously been isolated from different non-human sources.
Identiﬁcation methods, results obtained with three in vitro antifun-
gal susceptibility methods and clinical features are reported.
Keywords: Antifungal susceptibility, candida haemubaii, fungai
osteitis
Original Submission: 29 September 2010; Revised
Submission: 6 January 2011; Accepted: 12 January 2011
Editor: E. Roilides
Article published online: 24 January 2011
Clin Microbiol Infect 2011; 17: 1068–1070
10.1111/j.1469-0691.2011.03471.x
Corresponding author: N. Bourgeois, Laboratoire Parasitologie-
Mycologie, Groupe Hospitalo-universitaire Caremeau, Place du Pr.
Debre´, 30029 Nıˆmes Cedex 9, France
E-mail: nathalie.bourgeois@voila.fr
A 37-year-old man with a 20 pack a year cigarette-smoking
history consulted for left hallux wound worsening for a
period of 3 months. This economically deprived patient
reported hard living conditions, with a lack of hygienic condi-
tions, and walking barefoot. He described having, for 2 years,
symptoms of bilateral claudication of the lower limbs and
numbness, with a sensation of coldness of his left big toe.
He was afebrile, and physical examination disclosed left
hallux tenderness with redness and heat up to the left foot.
An ulceration of the left hallux was observed with necrotic
borders, extension to the ungueal matrix and a purulent exu-
date. Otherwise, popliteal, posterior tibial and dorsalis pedis
artery pulses were absent.
The white blood cell count was 5000 cells/mL. The C-
reactive protein level was 20 mg/L. Liver and renal function
test results were normal.
Doppler ultrasound showed no ﬂow at the left ankle, and
demonstrated that the left femoral superﬁcial and popliteal
arteries were occluded segmentally. The X-ray was sugges-
tive of osteitis by showing areas of osteolysis of the hallux
with lucencies of cortical and medullar bone, scalloping, and
periostal elevation. Medical treatment was attempted with
vasodilator drugs, without success. Finally, a surgical bypass
operation was performed without complications, during
which the patient underwent bone biopsy with excision of
necrotic tissue.
Histological examination revealed an irregularly arranged
trabecular bone and evidence of acute inﬂammation with
presence of polymorphonuclear leukocytes. Bone biopsy
specimens were taken for microbiological culture, and Gram
staining showed leukocytes but no bacteria. After 48 h of
incubation, several CFUs of yeast grew on blood agar med-
ium. The yeast isolate was cultivated on Sabouraud agar, and
identiﬁed as Candida haemulonii with the Vitek 2 system
(bioMe´rieux Craponne, France), whereas the ID32C system
(bioMe´rieux) did not lead to any full yeast identiﬁcation.
C. haemulonii identiﬁcation was then conﬁrmed by molecular
biology with internal transcribed spacer (ITS) regions of the
rRNA gene.
The C. haemulonii isolate was resistant to amphoteri-
cin B and itraconazole, dose-dependently susceptible to ﬂuco-
nazole with the Etest method, but susceptible to voriconazole.
Table 1 summarizes the MIC values obtained for all molecules
with three different antifungal susceptibility methods.
Antifungal treatment with oral voriconazole was initiated
at a loading dose of two 400-mg doses on the ﬁrst day, fol-
lowed by 200 mg administered twice daily and continued for
at least 6 months. C-reactive protein levels returned to nor-
mal after 3 months, and after 4 months of follow-up, the
hallux ulcer is healed and the patient remains well.
C. haemulonii has been reported to be implicated in inva-
sive infections, causing fungaemia or chronic otitis media
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[1–4]. Most fungal musculoskeletal infections have an insidi-
ous onset and an indolent course, and generally cause mild
inﬂammation with non-speciﬁc laboratory ﬁndings. Fungal
osteomyelitis can arise from direct inoculation or haematog-
enous dissemination of organisms. In the literature, Candida
albicans is the yeast most commonly isolated from cases of
osteitis. To our knowledge, this is the ﬁrst report of osteitis
caused by C. haemulonii. Infections with this organism have
concerned mostly immunocompromised patients or those at
the extremes of age [1,3,4]. Our patient had no immunodeﬁ-
ciency, but presented a vascular disease responsible for a
‘local immunodeﬁciency’, with a lack of hygienic conditions.
This is concordant with an environmental source of the
infection, as C. haemulonii has been isolated from marine
environments, ﬁsh (Haemulon sciurus) [5] and polluted
biotopes.
Given the conditions prevailing in such patients, even yeast
with low pathogenicity may cause an infection of foot ulcers.
Histological examination contributes to determining whether
fungal isolates are responsible for infection and not coloniza-
tion.
Identiﬁcation of the yeast isolate was performed with YST
Vitek 2 system cards (bioMe´rieux), and conﬁrmed by a
molecular method with ITS sequencing. The in vitro suscepti-
bilities to amphotericin B, ﬂuconazole, voriconazole and
caspofungin were ﬁrst routinely determined by the Etest
method (bioMe´rieux), and determination of susceptibilities
was then completed with posaconazole, itraconazole and
micafungin strips, and with the AST-YS01 Vitek 2 cards
system (bioMe´rieux) for amphotericin B, ﬂuconazole and
voriconazole, and the EUCAST method for amphotericin B,
ﬂuconazole, voriconazole, posaconazole and caspofungin. The
EUCAST method was performed by the Institut Pasteur of
Paris (F. Dromer), according to the EUCAST’s recommenda-
tions.
All of the methods were validated with quality control
strains ATCC 90028 (C. albicans), ATCC 22019 (Candida
parapsilosis) and ATCC 6258 (Candida krusei).
The interpretative breakpoints used were CLSI interpreta-
tive breakpoints [6] for the Etest method and AST-YS01 Vi-
tek 2 cards system, and suggested breakpoints for micafungin
and caspofungin. Interpretive criteria for amphotericin B and
posaconazole have not yet been deﬁned. For the EUCAST
method, non-species-related breakpoints were used for ﬂuco-
nazole (http://www.srga.org/eucastwt/MICTAB/index.html).
The isolation of this particular Candida species underlines
the importance of accurate identiﬁcation and reliable antifun-
gal susceptibility testing for the adaptation of treatment, espe-
cially in cases of invasive infection. Indeed, this species has
been reported to be resistant to amphotericin B [1,2,7] and
at least dose-dependently susceptible to ﬂuconazole [4,7],
which is in agreement with the results obtained with the Etest
method used routinely in our laboratory. Nevertheless, some
discrepancies could be observed when the three different
methods were compared (Table 1). Indeed, the results of the
Vitek 2 system are in total agreement for amphotericin B and
voriconazole (with a low MIC), but for ﬂuconazole, a lower
MIC of only 8 mg/L was determined. Moreover, the isolate
was found to be resistant to ﬂuconazole with the EUCAST
method, and also to posaconazole and voriconazole. The
patient had a favourable outcome after 4 months of adapted
antifungal therapy with voriconazole, avoiding amputation.
The duration of treatment is not well established, owing to
the low frequency of such infections; however, improved tis-
sue perfusion may be a key factor. Some commercial yeast
identiﬁcation systems, such as the ID32C system, have difﬁ-
culties in distinguishing C. haemulonii from other species,
owing to database limitations. This species, which has been
described as an emergent one [5,7], is still rarely isolated clin-
ically, and would perhaps be more satisfactorily identiﬁed with
new automated systems and molecular methods.
In summary, we describe a case of C. haemulonii septic
osteitis occurring in the context of peripheral arterial dis-
ease. Despite its low frequency, we suggest that there should
be prompt consideration of C. haemulonii infection in cases
of fungal osteitis with an absence of clinical response to
ﬂuconazole.
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TABLE 1. In vitro antifungal susceptibili-
ties of the Candida haemulonii isolate
determined by Etest, Vitek 2 and EU-
CAST methods
MICs (mg/L)
AB Fl Vo Po Itra Cas Mic
Etest method >32/R 32/SDD 0.38/S 0.094 ‡8/R 0.25/S 0.25/S
Vitek 2 system >16/R 8/S 0.25/S ND ND ND ND
EUCAST method 1 ‡64/R 4 >32/R ND 0.03/S ND
AB, amphotericin B; Fl, ﬂuconazole; Vo, voriconazole; Po, posaconazole; Itra, itraconazole; Cas, caspofungin;
Mic, micafungin; R, resistant; S, susceptible; SDD, dose-dependently susceptible; ND, not determined.
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